Surrogate end point scrutiny: A more evidence based approach to the use of surrogate end points in policy making

BMJ (Online)

Volumn 343, Issue 7829, 2011, Pages

  Ciani, Oriana ^a   Taylor, Rod S ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DECISION MAKING; EVIDENCE BASED PRACTICE; HEALTH CARE POLICY; LETTER; METHODOLOGY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RELIABILITY; SURROGATE OUTCOMES; VALIDATION STUDY; BLOOD; HUMAN; NOTE;

BIOLOGICAL MARKER;

BIOLOGICAL MARKERS; HUMANS;

EID: 84859004988     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d6498     Document Type: Letter

References (5)

1. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-13. (Pubitemid 126450094)
2. Moynihan R. Surrogates under scrutiny: fallible correlations, fatal consequences. BMJ 2011;343:d5160. (15 August.)
3. Weir CJ, Walley RJ. Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Stat Med 2006;25:183-203. (Pubitemid 43141502)
4. Taylor RS, Elston J. The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports. Health Technol Assess 2009;13:1-50.
5. Lassere MN. The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Stat Methods Med Res 2007;17:303-40.